***Background.*** Valley Fever (VF) is a respiratory disease caused by inhalation of *Coccidioides* spp. spores; prior infection confers lifelong immunity. During 2011, VF incidence at two highly endemic prisons (HEP) was \>100 times higher than surrounding areas. Screening inmates with a new delayed-type hypersensitivity skin test (Spherusol®) that identifies persons with prior *Coccidioides* infection could be used to populate HEP with immune inmates. Our objective was to estimate the change in VF incidence following implementation of a skin test screening program.

***Methods.*** We used Microsoft Excel to create a dynamic model of a hypothetical screening program where all California inmates are tested. Skin test-negative (non-immune) inmates are excluded from HEP; prisons are repopulated with skin test-positive inmates. Data from prison clinics on laboratory-confirmed infections were used to calculate predicted incidence rates, using 2011 mid-year population at HEP. We used published data for assumptions of prevalence of skin test positivity in different populations, and for skin test sensitivity and specificity. A sensitivity analysis varied prevalence of prior infection and test sensitivity and specificity.

***Results.*** Without a skin test screening program, we expect an annual incidence of 5.3% at HEP. According to the model, 87% of inmates will test negative and will be excluded from HEP when prevalence of prior infection is 9% among California inmates. Following re-population of HEP with skin test-positive inmates, the expected incidence will be 1.8% (61% decline, 268 cases prevented); inmates with false-positive Spherusol® tests will comprise 99% of subsequent infections. Sensitivity analysis demonstrated an expected incidence of 0.09-4.7% (12-98% decline; 54-432 cases prevented), largely influenced by prior infection prevalence and test specificity.

***Conclusion.*** Implementation of a hypothetical skin test-based screening program could sharply reduce incidence of VF at HEP. If implemented, additional studies to refine assumptions and evaluate the effectiveness of this program should be considered.
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